The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial to evaluate immune-related biomarkers for pathological response in stage II-III HER2-positive breast cancer receiving neoadjuvant chemotherapy with subsequent randomization to multi-epitope HER2 vaccine versus placebo in patients with residual disease post-neoadjuvant chemotherapy.
 
Saranya Chumsri
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Athenex; Athenex; bioTheranostics; bioTheranostics (Inst); Eisai; Immunomedics; Immunomedics; Immunomedics; Novartis; Novartis; Puma Biotechnology; Syndax
Research Funding - Array BioPharma; Merck
 
Nadine Norton
No Relationships to Disclose
 
Sarah Bruggeman
No Relationships to Disclose
 
David W. Hillman
No Relationships to Disclose
 
Brenda Ernst
No Relationships to Disclose
 
Kathryn Jean Ruddy
Research Funding - Medtronic (I)
Patents, Royalties, Other Intellectual Property - Spouse and Mayo Clinic are involved in a potential equity/royalty relationship with AliveCor. (I); Spouse and Mayo Clinic have filed patents related to the application of artificial intelligence to the electrocardiogram for diagnosis and risk stratification. (I)
 
Donald W. Northfelt
No Relationships to Disclose
 
Pooja Prem Advani
Stock and Other Ownership Interests - Abbvie (I); Alpha2 Pharmaceuticals (I); NanoString Technologies (I); Sorrento Therapeutics (I)
Honoraria - Ascentage Pharma Group (I); AstraZeneca (I)
Consulting or Advisory Role - Ascentage Pharma (I); AstraZeneca (I); BMS (I); Puma Biotechnology
Research Funding - Agendia; Ascentage Pharma (I); Ayala Pharmaceuticals (Inst); Bristol Myer Squibb (I); Genentech/Roche
Patents, Royalties, Other Intellectual Property - patent pending on PCT-US2020-067237 (cancer vaccine platform) (I)
Travel, Accommodations, Expenses - Tempus (I)
 
Kostandinos Sideras
No Relationships to Disclose
 
Alvaro Moreno-Aspitia
Stock and Other Ownership Interests - Merrimack
Research Funding - Abbvie (Inst); Daiichi Sankyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Sermonix Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from the development of a xenograft model. Royalties were assigned to go to my institution and not personally
 
Matthew P. Goetz
Consulting or Advisory Role - AstraZeneca (Inst); bioTheranostics; Biovica; Blueprint Medicines (Inst); Eagle Pharmaceuticals (Inst); Genzyme (Inst); Lilly; Novartis; Pfizer; Sermonix Pharmaceuticals
Research Funding - Lilly (Inst); Pfizer (Inst); Sermonix Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Development of Human Tumor Xenografts from Women with Breast Cancer Treated with Neoadjuvant Chemotherapy (Inst); Methods and Materials for Assessing Chemotherapy Responsiveness and Treating Cancer; METHODS AND MATERIALS FOR USING BUTYRYLCHOLINESTERASES TO TREAT CANCER
Travel, Accommodations, Expenses - Lilly
 
Keith L. Knutson
Patents, Royalties, Other Intellectual Property - Marker Therapeutics